The most frequently reported side effects include gastrointestinal symptoms such as nausea (occurring in more than 1 in 10 patients), diarrhoea, vomiting, constipation, and abdominal pain
The primary mechanism involves binding to GLP-1 receptors located throughout the body, particularly in the pancreas, brain, and gastrointestinal tract
9 This year, two major Canadian clinical practice guidelines, both for obesity (Canadian Adult Obesity Clinical Practice Guidelines) and diabetes (Diabetes Canada Clinical Practice Guidelines), have been updated to include semaglutide for patients who have MASH
A survey commissioned by LloydsPharmacy Online Doctor (survey size n=2,000, of those 285 are current and active users of GLP-1s for weight loss and 216 have recently stopped) found that 28% (n=140) of those surveyed who were using or had previously used weight-loss injections had knowingly bought from unlicensed sellers, 12% (n=60) think they may have done, and 20% (n=100) bought drugs that are unlicensed and untested for weight loss in the UK
.jpg)
